Eli Lilly Reports Positive Phase 3 Retatrutide Results
INDIANAPOLIS, July 23, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3 TRIUMPH-2 and...
Type 2 diabetes
Advertisement
Dexcom Selected as First Participant in FDA TEMPO Pilot Program
San Diego, July 22, 2026 Dexcom announced that it has become the first company selected by the U.S. Food...
Vivani Medical Partners with Novo Nordisk on NPM-139
ALAMEDA, Calif., July 7, 2026 Vivani Medical, Inc. has entered into a new strategic agreement with Novo Nordisk to...
Wave Life Sciences Initiates Phase 2a INLIGHT™ Trial of WVE-007 for Obesity and Cardiometabolic Diseases
CAMBRIDGE, Mass., June 24, 2026 Wave Life Sciences announced the initiation of the Phase 2a multidose portion of the...
Lilly’s Foundayo Outperforms Rivals in Landmark Diabetes Trials
INDIANAPOLIS, USA – June 8, 2026 Eli Lilly and Company has reported compelling new Phase 3 clinical data showing...
Advertisements
Novo Nordisk’s CagriSema Delivers Strong HbA1c and Weight Loss Results in Phase 3 REIMAGINE Trials
Plainsboro, New Jersey and Bagsværd, Denmark, June 7, 2026 Novo Nordisk has unveiled compelling Phase 3 clinical data for...
Lilly’s Foundayo Shows Strong Weight Loss Across Menopause
INDIANAPOLIS, Indiana, June 7, 2026 Eli Lilly and Company has announced new data demonstrating that Foundayo® (orforglipron), the only...
Tandem Diabetes Care Expands CE Mark for AID Systems
SAN DIEGO, June 5, 2026 Tandem Diabetes Care announced that its t:slim X2 and Tandem Mobi automated insulin delivery...
Ascletis Showcases Next-Generation Obesity Pipeline at ADA 2026
HONG KONG and NEW ORLEANS, Louisiana, June 8, 2026 Ascletis Pharma has strengthened its position in the highly competitive...
Berobenatide Shows Strong Weight Loss With Monthly Dosing
NEW ORLEANS, Louisiana, June 6, 2026 New data presented at the American Diabetes Association (ADA) 2026 Scientific Sessions have...
Advertisement
